Top

Published in:

Open Access 01-12-2014 | Review

Stereotactic Body Radiation Therapy (SBRT) for lung cancer patients previously treated with conventional radiotherapy: a review

Authors: Arya Amini, Norman Yeh, Laurie E Gaspar, Brian Kavanagh, Sana D Karam

Published in: Radiation Oncology | Issue 1/2014

Abstract

Lung cancer continues to be one of the most prevalent malignancies worldwide and is the leading cause of death in both men and women. Presently, local control rates are quite poor. Improvements in imaging and radiation treatment delivery systems however have provided radiation oncologists with new tools to better target these tumors. Stereotactic body radiation therapy (SBRT) is one such technique that has shown efficacy as upfront treatment for lung cancer. In addition, more recent studies have demonstrated some effectiveness in recurrent tumors in prior irradiated fields as well. This review summarizes seven recent studies of re-irradiation with SBRT in patients with thoracic recurrences treated previously with conventionally fractionated radiation therapy. Combined, 140 patients were included. The median initial thoracic radiation doses ranged from 50-87.5 Gy and median re-irradiation dose ranged from 40-80 Gy. Local control rates varied from 65-92%. Re-irradiation was well tolerated with few grade 4 and 5 complications (observed in one study). Currently, based on these published reports, re-irradiation with SBRT appears feasible for in-field thoracic recurrences, though caution must be taken in all cases of retreatment.

Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 2013, 63: 11-30. 10.3322/caac.21166CrossRefPubMed

Jeremic B, Shibamoto Y, Acimovic L, Nikolic N, Dagovic A, Aleksandrovic J, Radosavljevic-Asic G: Second cancers occurring in patients with early stage non-small-cell lung cancer treated with chest radiation therapy alone. J Clin Oncol 2001, 19: 1056-1063.PubMed

Carr SR, Schuchert MJ, Pennathur A, Wilson DO, Siegfried JM, Luketich JD, Landreneau RJ: Impact of tumor size on outcomes after anatomic lung resection for stage 1A non-small cell lung cancer based on the current staging system. J Thorac Cardiovasc Surg 2012, 143: 390-397. 10.1016/j.jtcvs.2011.10.023CrossRefPubMed

Le Chevalier T, Arriagada R, Quoix E, Ruffie P, Martin M, Tarayre M, Lacombe-Terrier MJ, Douillard JY, Laplanche A: Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991, 83: 417-423. 10.1093/jnci/83.6.417CrossRefPubMed

Leksell L: Stereotactic radiosurgery. J Neurol Neurosurg Psychiatry 1983, 46: 797-803. 10.1136/jnnp.46.9.797PubMedCentralCrossRefPubMed

Zhang J, Yang F, Li B, Liu J, Huang W, Wang D, Yi Y, Wang J: Which is the optimal biologically effective dose of stereotactic body radiotherapy for Stage I non-small-cell lung cancer? A meta-analysis. Int J Radiat Oncol Biol Phys 2011, 81: e305-e316. 10.1016/j.ijrobp.2011.04.034CrossRefPubMed

Martel MK, Ten Haken RK, Hazuka MB, Kessler ML, Strawderman M, Turrisi AT, Lawrence TS, Fraass BA, Lichter AS: Estimation of tumor control probability model parameters from 3-D dose distributions of non-small cell lung cancer patients. Lung Cancer 1999, 24: 31-37. 10.1016/S0169-5002(99)00019-7CrossRefPubMed

Fairchild A, Harris K, Barnes E, Wong R, Lutz S, Bezjak A, Cheung P, Chow E: Palliative thoracic radiotherapy for lung cancer: a systematic review. J Clin Oncol 2008, 26: 4001-4011. 10.1200/JCO.2007.15.3312CrossRefPubMed

Onishi H, Araki T, Shirato H, Nagata Y, Hiraoka M, Gomi K, Yamashita T, Niibe Y, Karasaw K, Hayakawa K, Takai Y, Kimura T, Hirokawa Y, Takeda A, Ouchi A, Hareyama M, Kokubo M, Hara R, Itami J, Yamada K: Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 2004, 101: 1623-1631. 10.1002/cncr.20539CrossRefPubMed

10.

Kavanagh BD, Timmerman RD: Stereotactic body radiation therapy. Philadelphia: Lippincott Williams & Wilkins; 2005.

11.

Noble J, Ellis PM, Mackay JA, Evans WK: Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol 2006, 1: 1042-1058. 10.1097/01243894-200611000-00021CrossRefPubMed

12.

Heron DE, Ferris RL, Karamouzis M, Andrade RS, Deeb EL, Burton S, Gooding WE, Branstetter BF, Mountz JM, Johnson JT, Argiris A, Grandis JR, Lai SY: Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trial. Int J Radiat Oncol Biol Phys 2009, 75: 1493-1500. 10.1016/j.ijrobp.2008.12.075CrossRefPubMed

13.

Roh KW, Jang JS, Kim MS, Sun DI, Kim BS, Jung SL, Kang JH, Yoo EJ, Yoon SC, Jang HS, Chung SM, Kim YS: Fractionated stereotactic radiotherapy as reirradiation for locally recurrent head and neck cancer. Int J Radiat Oncol Biol Phys 2009, 74: 1348-1355. 10.1016/j.ijrobp.2008.10.013CrossRefPubMed

14.

Timmerman RD, Kavanagh BD, Cho LC, Papiez L, Xing L: Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol 2007, 25: 947-952. 10.1200/JCO.2006.09.7469CrossRefPubMed

15.

Timmerman R, Papiez L, McGarry R, Likes L, DesRosiers C, Frost S, Williams M: Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 2003, 124: 1946-1955. 10.1378/chest.124.5.1946CrossRefPubMed

16.

Xia T, Li H, Sun Q, Wang Y, Fan N, Yu Y, Li P, Chang JY: Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006, 66: 117-125. 10.1016/j.ijrobp.2006.04.013CrossRefPubMed

17.

Nagata Y, Takayama K, Matsuo Y, Matsuo Y, Norihisa Y, Mizowaki T, Sakamoto M, Mitsumori M, Shibuya K, Araki N, Yano S, Hiraoka M: Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys 2005, 63: 1427-1431. 10.1016/j.ijrobp.2005.05.034CrossRefPubMed

18.

Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, Ewing M, Abdulrahman R, DesRosiers C, Williams M, Fletcher J: Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006, 24: 4833-4839. 10.1200/JCO.2006.07.5937CrossRefPubMed

19.

Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, Fakiris A, Bezjak A, Videtic G, Johnstone D, Fowler J, Gore E, Choy H: Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010, 303: 1070-1076. 10.1001/jama.2010.261PubMedCentralCrossRefPubMed

20.

Mantel F, Flentje M, Guckenberger M: Stereotactic body radiation therapy in the re-irradiation situation–a review. Radiat Oncol 2013, 8: 7. 10.1186/1748-717X-8-7PubMedCentralCrossRefPubMed

21.

Kelly P, Balter PA, Rebueno N, Sharp HJ, Liao Z, Komaki R, Chang JY: Stereotactic body radiation therapy for patients with lung cancer previously treated with thoracic radiation. Int J Radiat Oncol Biol Phys 2010, 78: 1387-1393. 10.1016/j.ijrobp.2009.09.070PubMedCentralCrossRefPubMed

22.

Trakul N, Harris JP, Le QT, Hara WY, Maxim PG, Loo BW Jr, Diehn M: Stereotactic ablative radiotherapy for reirradiation of locally recurrent lung tumors. J Thorac Oncol 2012, 7: 1462-1465. 10.1097/JTO.0b013e31825f22ceCrossRefPubMed

23.

Reyngold M, Wu AJ, McLane A, Zhang Z, Hsu M, Stein NF, Zhou Y, Ho AY, Rosenzweig KE, Yorke ED, Rimner A: Toxicity and outcomes of thoracic re-irradiation using stereotactic body radiation therapy (SBRT). Radiat Oncol 2013, 8: 99. 10.1186/1748-717X-8-99PubMedCentralCrossRefPubMed

24.

Coon D, Gokhale AS, Burton SA, Heron DE, Ozhasoglu C, Christie N: Fractionated stereotactic body radiation therapy in the treatment of primary, recurrent, and metastatic lung tumors: the role of positron emission tomography/computed tomography-based treatment planning. Clin Lung Cancer 2008, 9: 217-221. 10.3816/CLC.2008.n.032CrossRefPubMed

25.

Ester EC, Jones DA, Vernon MR, Yuan J, Weaver RD, Shanley RM, Andrade RS, Cho LC: Lung reirradiation with stereotactic body radiotherapy (SBRT). J Radiosurg & SBRT 2013, 2: 325-331.

26.

Seung SK, Solhjem M: Salvage SBRT for previously irradiated lung cancer. J Cancer Ther 2011, 2: 190-195. 10.4236/jct.2011.22024CrossRef

27.

Trovo M, Minatel E, Durofil E, Polasel J, Avanzo M, Baresic T, Bearz A, Del Conte A, Franchin G, Gobitti C, Rumeileh IA, Trovo MG: Stereotactic body radiation therapy for re-irradiation of persistent or recurrent non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2014, 88: 1114-1119. 10.1016/j.ijrobp.2014.01.012CrossRefPubMed

28.

Simone CB 2nd, Wildt B, Haas AR, Pope G, Rengan R, Hahn SM: Stereotactic body radiation therapy for lung cancer. Chest 2013, 143: 1784-1790. 10.1378/chest.12-2580CrossRefPubMed

29.

Liu H, Zhang X, Vinogradskiy YY, Swisher SG, Komaki R, Chang JY: Predicting radiation pneumonitis after stereotactic ablative radiation therapy in patients previously treated with conventional thoracic radiation therapy. Int J Radiat Oncol Biol Phys 2012, 84: 1017-1023. 10.1016/j.ijrobp.2012.02.020PubMedCentralCrossRefPubMed

30.

Evans JD, Gomez DR, Amini A, Rebueno N, Allen PK, Martel MK, Rineer JM, Ang KK, McAvoy S, Cox JD, Komaki R, Welsh JW: Aortic dose constraints when reirradiating thoracic tumors. Radiother Oncol 2013, 106: 327-332. 10.1016/j.radonc.2013.02.002PubMedCentralCrossRefPubMed

31.

Hiraki T, Gobara H, Iguchi T, Fujiwara H, Matsui Y, Kanazawa S: Radiofrequency ablation for early-stage nonsmall cell lung cancer. Biomed Res Int 2014, 2014: 152087.PubMedCentralCrossRefPubMed

32.

MacManus M, Nestle U, Rosenzweig KE, Carrio I, Messa C, Belohlavek O, Danna M, Inoue T, Deniaud-Alexandre E, Schipani S, Watanabe N, Dondi M, Jeremic B: Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006-2007. Radiother Oncol 2009, 91: 85-94. 10.1016/j.radonc.2008.11.008CrossRefPubMed

33.

Nestle U, Kremp S, Grosu AL: Practical integration of [18F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC): the technical basis, ICRU-target volumes, problems, perspectives. Radiother Oncol 2006, 81: 209-225. 10.1016/j.radonc.2006.09.011CrossRefPubMed

34.

Wang YC, Tseng HL, Lin YH, Kao CH, Huang WC, Huang TC: Improvement of internal tumor volumes of non-small cell lung cancer patients for radiation treatment planning using interpolated average CT in PET/CT. PLoS One 2013, 8: e64665. 10.1371/journal.pone.0064665PubMedCentralCrossRefPubMed

35.

Pommier P, Touboul E, Chabaud S, Dussart S, Le Pechoux C, Giammarile F, Carrie C: Impact of (18) F-FDG PET on treatment strategy and 3D radiotherapy planning in non-small cell lung cancer: a prospective multicenter study. AJR Am J Roentgenol 2010, 195: 350-355. 10.2214/AJR.09.3981CrossRefPubMed

36.

Machtay M, Duan F, Siegel BA, Snyder BS, Gorelick JJ, Reddin JS, Munden R, Johnson DW, Wilf LH, DeNittis A, Sherwin N, Cho KH, Videtic G, Neumann DR, Komaki R, Macapinlac H, Bradley JD, Alavi A: Prediction of survival by [18F] fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial. J Clin Oncol 2013, 31: 3823-3830. 10.1200/JCO.2012.47.5947PubMedCentralCrossRefPubMed

37.

Inoue T, Kim EE, Komaki R, Wong FC, Bassa P, Wong WH, Yang DJ, Endo K, Podoloff DA: Detecting recurrent or residual lung cancer with FDG-PET. J Nucl Med 1995, 36: 788-793.PubMed

38.

Bradley J, Thorstad WL, Mutic S, Miller TR, Dehdashti F, Siegel BA, Bosch W, Bertrand RJ: Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004, 59: 78-86. 10.1016/j.ijrobp.2003.10.044CrossRefPubMed

39.

Keall P: 4-dimensional computed tomography imaging and treatment planning. Semin Radiat Oncol 2004, 14: 81-90. 10.1053/j.semradonc.2003.10.006CrossRefPubMed

40.

Christodoulou M, Bayman N, McCloskey P, Rowbottom C, Faivre-Finn C: New radiotherapy approaches in locally advanced non-small cell lung cancer. Eur J Cancer 2014, 50: 525-534. 10.1016/j.ejca.2013.11.027CrossRefPubMed

41.

Gunderson LL, Tepper J: Clinical Radiation Oncology. 3rd edition. Philadelphia: Elsevier Health Sciences; 2011.

42.

Wulf J, Hadinger U, Oppitz U, Thiele W, Flentje M: Impact of target reproducibility on tumor dose in stereotactic radiotherapy of targets in the lung and liver. Radiother Oncol 2003, 66: 141-150. 10.1016/S0167-8140(02)00372-9CrossRefPubMed

43.

Vinogradskiy Y, Castillo R, Castillo E, Tucker SL, Liao Z, Guerrero T, Martel MK: Use of 4-dimensional computed tomography-based ventilation imaging to correlate lung dose and function with clinical outcomes. Int J Radiat Oncol Biol Phys 2013, 86: 366-371. 10.1016/j.ijrobp.2013.01.004CrossRefPubMed

44.

De Ruysscher D, Belderbos J, Reymen B, van Elmpt W, van Baardwijk A, Wanders R, Hoebers F, Vooijs M, Ollers M, Lambin P: State of the art radiation therapy for lung cancer 2012: a glimpse of the future. Clin Lung Cancer 2013, 14: 89-95. 10.1016/j.cllc.2012.06.006CrossRefPubMed

45.

Gressen EL, Werner-Wasik M, Cohn J, Topham A, Curran WJ Jr: Thoracic reirradiation for symptomatic relief after prior radiotherapeutic management for lung cancer. Am J Clin Oncol 2000, 23: 160-163. 10.1097/00000421-200004000-00011CrossRefPubMed

46.

Jeremic B, Videtic GM: Chest reirradiation with external beam radiotherapy for locally recurrent non-small-cell lung cancer: a review. Int J Radiat Oncol Biol Phys 2011, 80: 969-977. 10.1016/j.ijrobp.2011.01.069CrossRefPubMed

47.

Amini A, Lin SH, Wei C, Allen P, Cox JD, Komaki R: Accelerated hypofractionated radiation therapy compared to conventionally fractionated radiation therapy for the treatment of inoperable non-small cell lung cancer. Radiat Oncol 2012, 7: 33. 10.1186/1748-717X-7-33PubMedCentralCrossRefPubMed

48.

Feld R, Abratt R, Graziano S, Jassem J, Lacquet L, Ninane V, Paesmans M, Rocmans P, Schiepers C, Stahel R, Stephens R: Pretreatment minimal staging and prognostic factors for non-small cell lung cancer. Lung Cancer 1997,17(Suppl 1):S3-S10.CrossRefPubMed

49.

Nguyen LN, Komaki R, Allen P, Schea RA, Milas L: Effectiveness of accelerated radiotherapy for patients with inoperable non-small cell lung cancer (NSCLC) and borderline prognostic factors without distant metastasis: a retrospective review. Int J Radiat Oncol Biol Phys 1999, 44: 1053-1056. 10.1016/S0360-3016(99)00130-3CrossRefPubMed

50.

McDonald S, Rubin P, Phillips TL, Marks LB: Injury to the lung from cancer therapy: clinical syndromes, measurable endpoints, and potential scoring systems. Int J Radiat Oncol Biol Phys 1995, 31: 1187-1203. 10.1016/0360-3016(94)00429-OCrossRefPubMed

51.

Senthi S, Dahele M, van de Ven PM, Slotman BJ, Senan S: Late radiologic changes after stereotactic ablative radiotherapy for early stage lung cancer: a comparison of fixed-beam versus arc delivery techniques. Radiother Oncol 2013, 109: 77-81. 10.1016/j.radonc.2013.08.034CrossRefPubMed

52.

Dahele M, Palma D, Lagerwaard F, Slotman B, Senan S: Radiological changes after stereotactic radiotherapy for stage I lung cancer. J Thorac Oncol 2011, 6: 1221-1228. 10.1097/JTO.0b013e318219aac5CrossRefPubMed

Title: Stereotactic Body Radiation Therapy (SBRT) for lung cancer patients previously treated with conventional radiotherapy: a review
Authors: Arya Amini
Norman Yeh
Laurie E Gaspar
Brian Kavanagh
Sana D Karam
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: Radiation Oncology / Issue 1/2014
Electronic ISSN: 1748-717X
DOI: https://doi.org/10.1186/1748-717X-9-210

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Stereotactic Body Radiation Therapy (SBRT) for lung cancer patients previously treated with conventional radiotherapy: a review

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2014

Optimal beam arrangement for pulmonary ventilation image-guided intensity-modulated radiotherapy for lung cancer

Clinical observation of submandibular gland transfer for the prevention of xerostomia after radiotherapy for nasopharyngeal carcinoma: a prospective randomized controlled study of 32 cases

Effects of the dose-volume relationship on and risk factors for maxillary osteoradionecrosis after carbon ion radiotherapy

A cohort analysis to identify eligible patients for intraoperative radiotherapy (IORT) of early breast cancer

Hypofractionated radiotherapy for breast cancer acceleration of the START A treatment regime: intermediate tolerance and efficacy

SPECT/CT lymphoscintigraphy of sentinel node(s) for superselective prophylactic irradiation of the neck in cN0 head and neck cancer patients: a prospective phase I feasibility study